Last Updated: August 3, 2026

LINAGLIPTIN AND METFORMIN HYDROCHLORIDE Drug Patent Profile

✉ Email this page to a colleague

« Back to Dashboard

When do Linagliptin And Metformin Hydrochloride patents expire, and when can generic versions of Linagliptin And Metformin Hydrochloride launch?

Linagliptin And Metformin Hydrochloride is a drug marketed by Dr Reddys, MSN, Sunshine, and Zydus Pharms. and is included in four NDAs.

The generic ingredient in LINAGLIPTIN AND METFORMIN HYDROCHLORIDE is linagliptin; metformin hydrochloride. There are nineteen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the linagliptin; metformin hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Linagliptin And Metformin Hydrochloride

A generic version of LINAGLIPTIN AND METFORMIN HYDROCHLORIDE was approved as linagliptin; metformin hydrochloride by SUNSHINE on August 30^th, 2021.

Start Trial

AI Deep Research

Questions you can ask:

What is the 5 year forecast for LINAGLIPTIN AND METFORMIN HYDROCHLORIDE?
What are the global sales for LINAGLIPTIN AND METFORMIN HYDROCHLORIDE?
What is Average Wholesale Price for LINAGLIPTIN AND METFORMIN HYDROCHLORIDE?

Summary for LINAGLIPTIN AND METFORMIN HYDROCHLORIDE

US Patents:	0
Applicants:	4
NDAs:	4

US Patents and Regulatory Information for LINAGLIPTIN AND METFORMIN HYDROCHLORIDE

+ Get email alerts for changes to this table

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Dr Reddys	LINAGLIPTIN AND METFORMIN HYDROCHLORIDE	linagliptin; metformin hydrochloride	TABLET;ORAL	208427-003	Nov 3, 2025	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Sunshine	LINAGLIPTIN AND METFORMIN HYDROCHLORIDE	linagliptin; metformin hydrochloride	TABLET;ORAL	208336-003	Aug 30, 2021	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Msn	LINAGLIPTIN AND METFORMIN HYDROCHLORIDE	linagliptin; metformin hydrochloride	TABLET;ORAL	208459-003	Nov 3, 2025	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Zydus Pharms	LINAGLIPTIN AND METFORMIN HYDROCHLORIDE	linagliptin; metformin hydrochloride	TABLET;ORAL	208449-002	Mar 30, 2023	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Sunshine	LINAGLIPTIN AND METFORMIN HYDROCHLORIDE	linagliptin; metformin hydrochloride	TABLET;ORAL	208336-001	Aug 30, 2021	AB	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.